[Abstract] Objective To investigate the efficacy of Qianglianin in the treatment of allergic purpura. Methods To apply 30~80ml intravenous drip of Powernine injection once a day; and to set up a control group for observation, to apply 150~250ml intravenous drip of Salvia injection once a day. The two groups were supplemented with vitamin C and antihistamine drugs. The efficacy of the treatment group was significantly better than that of the control group (P<0.05). Conclusion: The efficacy of Qianglianin in the treatment of allergic purpura was significant. [Key words] Allergic purpura Allergic purpura (anaphylactoid purpura, AP) is a relatively common disease in dermatology. Its prevalence has been increasing year by year [1]. There is no specific treatment, and most of them are based on comprehensive treatment. From January 2002 to January 2004, we treated 36 cases of AP with the application of Dextran, and the efficacy was remarkable. Now we report as follows: 1. Information and methods 1.1 General information 69 patients with allergic purpura were selected, and all of them were diagnosed and typed according to the criteria in the fifth edition of Dermatologic Venereology edited by Zhang Xuejun. Among them, 38 cases were male and 31 cases were female; age ranged from 1 to 50 years old, average 16.2 years old; onset time ranged from 3 to 50 days; 46 cases were first-episode and 23 cases were recurrent; 9 cases were abdominal type, 11 cases were joint type, 16 cases were renal type, 10 cases were mixed type, (all the above types were mild to moderate) and 23 cases were simple type. We randomly divided into 2 groups, 36 cases in the treatment group and 33 cases in the control group. The two groups were similar in terms of disease duration, condition, age and gender, and were comparable. 1.2 Treatment method The treatment group was treated with intravenous injection of Qianglianing (provided by Wuxi Seventh Pharmaceutical Co., Ltd.), 30~80ml each time, in 5% glucose injection 250~500ml, once a day, for 2 weeks. In the control group, 150~250ml of Danshen injection (provided by Shanghai Changzheng Fumin Pharmaceutical Co., Ltd.) was administered intravenously once a day for the same duration as the treatment group. Both groups were supplemented with vitamin C (2.0~3.0g/d IV) and antihistamines, and no other drugs were used. Patients whose indexes were normal after treatment were monitored once every 2 weeks for 3 months. 1.3 Efficacy criteria Cured: all symptoms and signs disappeared, urine test was normal, fecal occult blood was negative, no recurrence for 3 months; Significant: symptoms basically disappeared, skin lesions subsided ≥ 60%, urine test and fecal occult blood improved significantly; Effective: symptoms reduced, skin lesions subsided ≥ 30%, urine test and fecal occult blood improved; Ineffective: symptoms did not improve significantly or aggravated, skin lesions subsided < 30% or increased, urine test and fecal occult blood did not Change or aggravation. 2, the results of the treatment group healed 16 cases, apparent effect 12 cases, effective 6 cases, invalid 2 cases, apparent efficiency 77.78%; control group healed 8 cases, apparent effect 9 cases, effective 11 cases, invalid 5 cases, apparent efficiency 51.52%. The difference between the two groups was significant (corrected x2= 4.14, P<0.05). The mean times of disappearance of skin symptoms, gastrointestinal symptoms, joint symptoms and urinary changes after treatment in the treatment and control groups were 6.3 and 9.5 days; 5.0 and 9.0 days; 3.5 and 6.0 days; 8.6 and 12.3 days, respectively. No adverse effects were observed during the treatment period in either group of cases. AP is caused by the deposition of immune complexes in the vessel wall, which activates complement and leads to inflammation in and around the capillary and small vessel walls and increases the permeability of the vessel wall, resulting in purpura and various local and systemic symptoms. However, the exact mechanism of immune complex formation is not clear. In recent years, it has been found that the number of CD4+ T lymphocytes and CD4+/CD8+ ratio decreased significantly in the acute phase of AP patients, while the number of immunoglobulin IgA and IgM increased in the recovery phase, suggesting that the relative changes in Th/Tc cells in AP patients may lead to an increase in the number of activated B cells and the production of large amounts of immunoglobulins, resulting in the deposition of circulating immune complexes[2,3] . . Another study found that doxycycline elevated CD4+ T lymphocytes[4] . Based on the above findings, it is suggested that doxycycline inhibits antibody production in AD patients, thus reducing the formation of immune complexes and mitigating skin and organ damage. Glycyrrhetinic acid, the degradation product of glycyrrhizin, the main drug component of strongine injection, blocks the inactivation of corticosteroids in the liver so that the drug exhibits significant corticosteroid-like effects[5] , resulting in anti-inflammatory and anti-allergic therapeutic effects on AP; the other drug components of the drug, cysteine and glycine, inhibit the potential steroid-like side effects of glycyrrhetinic acid[5] . Strongylin also has antioxidant effects, protects the membrane structure of organelles and blocks Ca2+ inward flow[6] , thus reducing organ damage and dilating vascular smooth muscle and improving microcirculation. The data of this group showed that the apparent efficiency of the treatment group (77.78%) was higher than that of the control group (51.52%), and the difference was significant ( P<0.05); it was better than that of the control group in terms of disappearance of clinical symptoms and recovery of urine protein. This indicates that doxycycline has better therapeutic effect on AP. The mechanism may be related to the above pharmacological effects of doxycycline. No adverse effects were observed in all patients during the treatment period. In conclusion, the treatment of AP with doxycycline has the following characteristics: fast onset of action, long-lasting effect, high cure rate, low side effects, sufficient drug supply, and low price. It can be recommended as the first-line drug for the treatment of AP.